News

The decision target action date was July 7, 2024. At this time, there is no indication from the federal agency to extend the date further.

Annie Certo, MA, and AJ Harris, MS, break down what a “summer slump” is and how it can affect children during summer break from school. The duo offers suggestions on how to combat the negative associations of a “summer slump.”

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

"Parents still ask about this. Indeed, many years ago the FDA approved a prescription form of a PUFA, Vayarin, for the treatment of patients with ADHD. It is no longer available, so I assume it did not work. There may be good reasons for taking a PUFA supplement, but having ADHD is not one of them." -Jon Matthew Farber, MD

Brief but practical reminders to help prevent drowning in children from the perspective of an emergency medicine fellow.

Results confirmed that a bedaquiline-containing regimen offered a significant improvement in treatment outcomes compared to injectable-containing regimens.

Matthew M. Davis, MD, MAAP, breaks down a newly-published study highlighting a potential association between COVID-19 vaccination and prevalence of symptomatic childhood asthma.

A discussion evaluating how social media can impact an individual's mental health, and what specific elements of social media could be causing it.

FDA decisions for the 2 accepted NDAs have target action dates of December 29 and December 30, 2024, respectively.

The submission to the FDA includes data from the phase 2b ReNeu trial of patients aged 2 years and older with NF1-associated PN causing significant morbidity.

"Obesity and treatment with growth hormone in children with PWS are known risk factors for hypoventilation as well as OSAS."- Jon Matthew Farber, MD

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The primary endpoint of the study was to measure childhood stigma related to disease visibility.

New data for FDA-approved dupilumab (Dupixent; Regeneron and Sanofi) highlights positive study results for the eosinophilic esophagitis (EoE) treatment in children aged 1 to 11 years.

A retracted paper that erroneously claimed the measles, mumps and rubella (MMR) vaccine caused autism has repercussions still being felt today around topics such as vaccination, misinformation and disinformation, and measles incidence rates.

Shreya Doshi, MBBS, FAAP, explains what health care sustainability is and how the industry contributes to climate change.

"I suspect that some doctors still have not changed their ways, so if you see your ENT, EM, or pediatric colleagues prescribing them, please ask them to stop." - Jon Matthew Farber, MD.

"This decision will have serious health consequences for children and young people," stated the president of the American Academy of Pediatrics.

How providers can advocate for increased research determining social media and its association with youth mental health.

The first thought that emerges is: how can we, as strong and persistent advocates for children and health equity, effectively remove barriers for accessing care that is driven by a dependency on financial resources?

Investigators therefore concluded that ROAR provides an excellent way to identify children at highest risk of having poor reading skills.

The decision makes pitolisant the first and only FDA-approved, non-scheduled treatment option for daytime sleepiness in this patient population.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

For ambulatory Duchenne patients, delandistrogene moxeparvovec-rokl was granted traditional approval, while accelerated approval was granted for non-ambulatory patients.

The disparity among specialist care for children with Medicaid vs private insurance was further widened for children with persistent asthma.

Participants included adolescents aged 13 to 17 years with severe obesity, defined as at or greater than 120% of the 95th BMI percentile.

The tool, the Kaiser Permanente neonatal EOS calculator, is designed to guide decision making based on objective data available at birth.

A discussion and explanation of metatarsus adductus, why screening is important, and the UNFO brace for treatment.

Findings "suggest that LUS is a promising tool for estimating respiratory outcomes in the first 2 years of life," wrote the study investigators.

The company also announced that it has surpassed its interim analysis enrollment target and expects topline phase 3 data from the FORTIFY study (NCT05775848) among individuals with LGMD21/R9 in 2025.